Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) is anticipated to post its quarterly earnings results after the market closes on Tuesday, March 11th. Analysts expect Zevra Therapeutics to post earnings of ($0.39) per share and revenue of $8.93 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Zevra Therapeutics Price Performance

NASDAQ ZVRA opened at $8.10 on Friday. The stock’s 50-day moving average price is $7.97 and its two-hundred day moving average price is $8.13. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market cap of $432.35 million, a PE ratio of -4.11 and a beta of 1.98. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76.

Insider Activity at Zevra Therapeutics

In other news, EVP Joshua Schafer sold 10,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $82,530.00. Following the completion of the sale, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the sale, the chief financial officer now directly owns 51,361 shares of the company’s stock, valued at $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have issued reports on the company. Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Guggenheim set a $21.00 target price on Zevra Therapeutics and gave the company a “buy” rating in a report on Tuesday, February 4th. Finally, Canaccord Genuity Group dropped their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $21.71.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.